A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

To join this study, you would generally need to be at least 18 years old. Your overall health and ability to perform daily activities would be checked, and you would need to be in a reasonably good condition. Your thyroid gland, which produces important hormones, would also need to be working normally. For women who could become pregnant, a pregnancy test would be required to be negative.

There are also some things that would prevent you from joining. For example, if you have other serious uncontrolled health problems like a severe infection, serious heart conditions, or uncontrolled high blood pressure or diabetes. You also wouldn't be able to join if you've previously been treated with similar types of immunotherapy drugs, or if you've recently had other cancer treatments. Also, if you’re pregnant, breastfeeding, or planning to become pregnant, you wouldn't be able to participate.

Taking part in this study would involve a series of visits to the clinic. Initially, there would be screening tests to confirm you meet all the requirements. Once enrolled, you would receive the study drug, JNJ-63723283, likely through an IV (into a vein). During your time on the study, you would have regular appointments for physical examinations, blood tests, and scans to monitor your health and how the treatment is affecting your cancer. For some parts of the study, a fresh sample of your tumour tissue might be needed before starting the treatment. The total duration of your participation would depend on how your body responds to the treatment and the study plan, but it will involve ongoing follow-up to monitor your health and any long-term effects. The research team will explain the full schedule and commitment.